Lupin Ltd (BSE: 500257) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹92,087 Cr, it ranks #128 by market cap among the 6,197 Indian listed companies on FinBizNet, and #8 of 86 in Medicinal Chemicals and Botanical Products. At ₹1,980.30 (as of 16 Nov 2026), the share price is 21.7% below its 52-week high of ₹2,529.50 and 4.6% above its 52-week low of ₹1,892.90. The share price is up 0.4% over one year and down 12.0% over three months.
| Current Price | ₹1,980.30 |
|---|---|
| Market Cap | ₹92,087 Cr |
| BSE Code | 500257 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 17.3 |
| Return on Equity | 26.91% |
| Return on Assets | 12.71% |
| 52-Week Range | ₹1,892.90 – ₹2,529.50 |
| 1-Year Price Change | +0.4% |
| 3-Month Price Change | -12.0% |
| Beta (1Y) | 0.22 |
| Dividend Yield | 0.89% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.lupin.com |
| Revenue | ₹7,827 Cr |
|---|---|
| Net Profit | ₹1,155 Cr |
| Net Margin | 14.8% |
| EPS (Basic) | ₹25.27 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Lupin Ltd reported revenue of ₹7,827 Cr in Q2 FY27, up 11.1% from ₹7,048 Cr in Q2 FY26 and down 5.4% from ₹8,277 Cr in Q1 FY27. It posted a net profit of ₹1,155 Cr for the quarter, against a net profit of ₹1,485 Cr in Q2 FY26 (down 22.2%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹5,667 Cr (Q4 FY25) to ₹8,277 Cr (Q1 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹7,827 Cr | ₹1,155 Cr | 14.8% |
| Q1 FY27 | ₹8,277 Cr | ₹1,417 Cr | 17.1% |
| Q4 FY26 | ₹7,475 Cr | ₹1,469 Cr | 19.6% |
| Q3 FY26 | ₹7,168 Cr | ₹1,181 Cr | 16.5% |
| Q2 FY26 | ₹7,048 Cr | ₹1,485 Cr | 21.1% |
| Q1 FY26 | ₹6,268 Cr | ₹1,221 Cr | 19.5% |
| Q4 FY25 | ₹5,667 Cr | ₹782 Cr | 13.8% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 46.84% of Lupin Ltd's shares as of Sept 2026, against 46.90% in Sept 2025 (−0.06 percentage points). Delivery averaged 54.0% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company also offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, women’s health, and central nervous system areas, as well as pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies. In addition, it focuses on various therapeutic spectrum, including rheumatology, oncology, neuroscience, and renal therapies. Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro
1. Pharmaceuticals-This segment manufactures and sells pharmaceuticals.
1. Pharmaceuticals-99.5% 2. Others-0.5%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Glenmark Pharmaceuticals Limited | ₹75,556 Cr | 55.1 | 14.07% | ₹4,157 Cr | +45.7% |
Listed by market capitalisation. Ratios are shown for context only.
Lupin Ltd is trading at ₹1,980.30, with a market capitalisation of ₹92,087 Cr.
Lupin Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Lupin Ltd has a P/E of 17.3 and a return on equity of 26.91%.
Lupin Ltd is listed on the BSE under the scrip code 500257.
Lupin Ltd's share price is up 0.4% over one year and down 12.0% over three months. Its 52-week range is ₹1,892.90 to ₹2,529.50.
In Q2 FY27, Lupin Ltd reported revenue of ₹7,827 Cr and net profit of ₹1,155 Cr, with basic EPS of ₹25.27 (consolidated, parsed from the company's exchange filing).
Lupin Ltd reported revenue of ₹7,827 Cr in Q2 FY27, up 11.1% from ₹7,048 Cr in Q2 FY26 and down 5.4% from ₹8,277 Cr in Q1 FY27.
Promoters held 46.84% of Lupin Ltd's shares as of Sept 2026, against 46.90% in Sept 2025 (−0.06 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.